TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05806606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dyadic empowerment based heart failure management program
Description: The 16-week De-HF Program is delivered on a dyadic basis, The program consists of three core elements: i) joint dyadic interview in a home visit (1st-2nd week), ii) five ICT-enhanced empowerment-based modules (3rd-12th week; 2 sessions/ each module), and iii) post-module telephone follow-up (13th-16th week). The overall aim of the dyadic interview is to understand their usual pattern of collaboration, deficits, strengths and competing concerns in disease management. This is followed by the empowerment modules with the purpose to help the care dyads to get a consensus in disease interpretation (1st session: Perceptual and Cognitive Empowerment Session) and develop collaborative goal attainment process (2nd Session: Collaborative Gaol-Setting Process). This will be followed by two bi-weekly telephone calls to the care dyads using a speaker phone to monitor their level of goal attainment for the five modules, and to give further advice and counselling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dyadic education program
Description: The 16-week HF education program comprises a home visit, five bi-weekly online training sessions, and the subsequent telephone follow-up for the care dyads. The nurse will first assess how they manage HF in terms of medication compliance, fluid and dietary control, symptom monitoring and responses in a home visit and clarify their major misconceptions in self-care. This will be followed by five bi-weekly online education sessions on the same topics as the empowerment modules in the De-HF program.
Study: NCT06042309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rubber accelerators and control chamber/solution for NON-SLS group
Description: Repeated exposure to rubber accelerators and control chamber/solution on arms. Three different concentrations of rubber accelerators and one control chamber/solution will be applied on the arms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rubber accelerators and control chamber/solution for NON-SLS group
Description: Repeated exposure to rubber accelerators and control chamber/solution on arms. Three different concentrations of rubber accelerators and one control chamber/solution will be applied on the arms.
Study: NCT01351090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: 10 mg Intranasal (2 x 100 uL of a 5% solution)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac tromethamine
Description: 30 mg Intranasal (2 x 100 uL of a 15% solution)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intranasal
Study: NCT05454995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vessel Restoration System (VRS)
Description: Vessel Restoration System (VRS) for the Treatment of Atherosclerotic Lesions in the Superficial Femoral Artery (SFA) and/or Proximal Popliteal Artery (PPA)
Study: NCT05704205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NB-UVB phototherapy
Description: Narrowband ultraviolet B irradiation 3 times a week

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Optimal topical therapy
Description: A combination of detailed instructions about the disease and treatments by trained nurses, bathing and washing advices, adequate emollients use, avoidance of triggers (including possible and proven contact allergens), fingertip unit explanation for active topical therapy, and personalized topical therapy with different potency topical steroids, calcineurin inhibitors and tar ointments

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Optimal topical therapy
Description: A combination of detailed instructions about the disease and treatments by trained nurses, bathing and washing advices, adequate emollients use, avoidance of triggers (including possible and proven contact allergens), fingertip unit explanation for active topical therapy, and personalized topical therapy with different potency topical steroids, calcineurin inhibitors and tar ointments
Study: NCT04724603

Intervention type: OTHER
Intervention: patients having had avderse event after phagotherapy for bone or joint or implant infection
Description: to determine the accountability of adverse effects in having had avderse event after phagotherapy for bone or joint or implant infection
Study: NCT04878055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reparixin
Description: 2 tablets of Reparixin (600 mg each), for the total of three daily administrations (6 tablets daily).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo, i.e. 2 tablets for the total of three daily administrations (6 tablets daily).
Study: NCT05258734

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COVOS app
Description: In this study, the patients in the experimental group will be followed up with the COVOS app and nursing interventions (videos, information messages) to manage their symptoms will be directed with the COVOS app.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: In this study, the patients in the control group will not receive any intervention, the standard follow-up and health care provided by the family health center of the patients will continue.
Study: NCT03972384

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-ICU Problem Solving
Description: We have adapted the Cognitive Orientation to Daily Occupational Performance (CO-OP) as the Post-ICU Problem Solving intervention to be delivered in the home to patients following an illness that required an ICU stay. CO-OP is a form of meta-cognitive strategy training that teaches individuals to identify and prioritize problematic daily activities, identify barriers impeding performance, generate and evaluate strategies addressing these barriers, and generalize learning through practice. Thus, strategy training teaches skills that can be used to address disability in real-life activities, and is integral to personalized rehabilitation services. CO-OP has been adapted in numerous settings and most recently, it is being utilized successfully in patients with acquired cognitive dysfunction following acute stroke. This represents a useful intervention, tested in similar populations with minimal risk to the participants and potential for maximal benefit for this population.
Study: NCT05684289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986278
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sildenafil
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study: NCT06185738

Intervention type: OTHER
Group type: OTHER
Intervention: WCM app
Description: WCM app evaluation at baseline, at completion of WCM program and 4 weeks after completion of WCM program, by completing PROMIS and Self Efficacy for managing disease scale questionnaires
Study: NCT06042309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLS
Description: Exposure to SLS on a randomized arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SLS
Description: Exposure to SLS on a randomized arm

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rubber accelerators and control chamber/solution for SLS group
Description: Repeated exposure to rubber accelerators and control chamber/solution on arms. Two different concentrations of rubber accelerators and one control chamber/solution will be applied on both arms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rubber accelerators and control chamber/solution for SLS group
Description: Repeated exposure to rubber accelerators and control chamber/solution on arms. Two different concentrations of rubber accelerators and one control chamber/solution will be applied on both arms.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch test on back
Description: Patch test on the back with thiurams or carbamates in different concentrations and a control chamber/solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch test on back
Description: Patch test on the back with thiurams or carbamates in different concentrations and a control chamber/solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch test on back
Description: Patch test on the back with thiurams or carbamates in different concentrations and a control chamber/solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch test on back
Description: Patch test on the back with thiurams or carbamates in different concentrations and a control chamber/solution
Study: NCT06208527

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nicotinamide Riboside (NR)
Description: A total of 2000 mg NR is administered daily for 1 year.
Study: NCT05063578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine 2% Injectable Solution
Description: Different concentration of lidocaine, injected via axillary block for arterio-venous fistula creation surgery
Study: NCT06285799

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Dose IHAT
Description: Once daily dose of 1 IHAT capsule (100mg IHAT per capsule) and once daily dose of 1 placebo capsule (carob flour)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose IHAT
Description: Twice daily dose of 1 IHAT capsule (100mg IHAT per capsule)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carob Flour
Description: Twice daily dose of 1 placebo capsule (carob flour)
Study: NCT06208527

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablet identical in taste, shape and appearance to NR tablets.
Study: NCT05027477

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radical Prostatectomy
Description: If you are in this group, you will get the standard of care treatment used to treat this type of cancer: radical prostatectomy. You will undergo this procedure as per standard clinical practice. A radical prostatectomy is a surgical procedure that removes the prostate gland. This is done by making a surgical incision and removing the prostate gland.
Study: NCT06169306

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: throat pack
Description: Following endotracheal intubation, one saline soaked, throat pack will inserted into the hypopharynx under direct vision. The packs will record in writting on the anaesthesia safety form.
Study: NCT05027477

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TULSA Procedure
Description: If you are in this group, you will get the TULSA Procedure. The TULSA Procedure is a minimally invasive procedure that uses directional ultrasound to produce very high temperature to ablate (destroy) targeted prostate tissue. The procedure is performed in a MRI suite (the physician can see the prostate at all times throughout the procedure) and uses the TULSA-PRO system to ablate prostate tissue. The procedure combines real-time MRI with robotically-driven directional thermal ultrasound to deliver predictable, physician-prescribed ablation of the prostate. Minimally invasive here means that the procedure is performed through natural openings in your body (the urethra) instead of creating larger openings like in traditional surgery.
Study: NCT06445322

Intervention type: DIAGNOSTIC_TEST
Intervention: Prescreening Assessments
Description: Various genetic and visual assessments.
Study: NCT05599984

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-706
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-706
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-706
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-706
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-706
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-706
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budigalimab
Description: IV Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous infusion
Study: NCT06446661

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Intensity
Description: Daily texts

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Text Messagings
Description: Standard Care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Text Messaging
Description: Weekly Texts
Study: NCT05858164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2862789
Description: Oral administration, solution or tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY2862789
Description: Oral administration, solution or tablets
Study: NCT04952129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selenomethionine
Description: Seleno-amino acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylselenocysteine
Description: Seleno-amino acid
Study: NCT06360328

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: video laryngoscopy
Description: The residents used video laryngoscopy for endotracheal intubation
Study: NCT04171622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT04691817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: 1200mg infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Tocilizumab 6mg/kg or 4mg/kg infusion
Study: NCT05562752

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: multistrain probiotic in the form of a capsule with a daily dose of 1E+9 Colony Forming Unit (CFU) per day for 12 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo in a form of a capsule for 12 weeks.
Study: NCT06434675

Intervention type: OTHER
Intervention: No intervention done
Description: No intervention done
Study: NCT06405178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Insulin Sensitizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Sodium-Glucose Co-transporter-2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin/Metformin
Description: Anti diabetic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromataze inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromataze inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Aromataze inhibitor
Study: NCT05934123

Intervention type: BEHAVIORAL
Intervention: EMNODN NEC Care Bundle
Description: A care bundle created by the East Midlands Neonatal Operational Delivery Network to guide neonatal services in the region to implement practices that support own mother's milk feeding and other interventions that may reduce the risk of NEC in babies born \<32 weeks' gestational age.
Study: NCT05645042

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transcendental Meditation (TM)
Description: During the first week, each participant randomized to undergo TM will meet with a TM instructor on four consecutive days for 60 minutes, for an introductory training. Next, participants will meet for twelve 60-minute sessions over the course of three months and then once monthly for booster sessions for 6 months. All sessions will be recorded and reviewed for adherence to the TM protocol.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Therapy (PCT)
Description: PCT treatments will be delivered by trained clinicians at master's or doctoral-level. Study therapists will be supervised by a a licensed psychologist. Participants assigned to this treatment will meet with a PCT therapist once a week for twelve 60-minute sessions over the course of 3 months and then monthly for months four through nine. Sessions will focus on current life problems as manifestations of PTSD. All sessions will be recorded and reviewed for adherence to the treatment protocol.
Study: NCT06008054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-B003
Description: Administered by intravenous infusion every 3 weeks (Q3W).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-B01D1
Description: Administered by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Monoclonal Antibody
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06404749

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: fungal fiber
Description: fungal fiber from mycelium

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: inulin
Description: long chain, degree of polymerization DP\>23
Study: NCT04719598

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: congnitive behavioural therapy
Description: CBT Sessions divide into three main components; 1) cognitive interventions, concerns with cognitive restructuring attempts to change maladaptive thought about thoughts about sleep into more adaptable . 2) Behavioral intervention: concerns with Relaxation training, stimulus control, and sleep restriction promote relaxation and help to establish healthy sleep habits. 3) Psychoeducational interventions: Providing information about the connection between thoughts, feelings, behaviors, and sleep.
Study: NCT05288946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local segmental control and closed kinetic chain
Description: the patients will receive Lumbar multifidus activation and Transversus abdominis activation then closed kinetic chain exercise in the form of Stand-up position on unstable surface, Closed chain lunge exercises, with the addition of hand weights, Bridge in prone position, Bridge in supine position, Lateral Bridge

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local segmental control and open kinetic chain
Description: the patients will receive Lumbar multifidus activation and Transversus abdominis activation then open kinetic chain in the form of Lower limb abduction, Knee extension in a supine position on a roller, Open chain exercise of the upper limb after co-contraction of transversus abdominis and multifidus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional therapy
Description: the patients will receive exercise in the form of Sitting knee raise on gym ball to maintain stability in the presence of hip movement on a reduced base of support, abdominal slide to control action of the rectus abdominis while moving, Lying trunk curl with leg lift to strengthen upper and lower abdominals (figure 1-6), Basic superman to strengthen the spinal and hip extensors

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional therapy
Description: the patients will receive exercise in the form of Sitting knee raise on gym ball to maintain stability in the presence of hip movement on a reduced base of support, abdominal slide to control action of the rectus abdominis while moving, Lying trunk curl with leg lift to strengthen upper and lower abdominals (figure 1-6), Basic superman to strengthen the spinal and hip extensors

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional therapy
Description: the patients will receive exercise in the form of Sitting knee raise on gym ball to maintain stability in the presence of hip movement on a reduced base of support, abdominal slide to control action of the rectus abdominis while moving, Lying trunk curl with leg lift to strengthen upper and lower abdominals (figure 1-6), Basic superman to strengthen the spinal and hip extensors
Study: NCT06056635

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karl Storz Curved Scope
Description: The curved fetoscope (11508AAK) will be used to view target areas during in-utero procedures for patients with a placenta that sits at the front of the uterus. There are various fetal conditions that may require use of a fetoscope during minimally invasive surgery. These include the need to seal vessels in order to stop blood flow going in a specific direction during pregnancy, abnormal vessels that may need to be sealed, or to break down scar tissue, extra tissue attachments, or blockages.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Karl Storz Straight Scope
Description: The straight fetoscope (11506AAK) will be used to view target areas during in-utero procedures for patients with a placenta that sits at the back of the uterus. There are various fetal conditions that may require use of a fetoscope during minimally invasive surgery. These include the need to seal vessels in order to stop blood flow going in a specific direction during pregnancy, abnormal vessels that may need to be sealed, or to break down scar tissue, extra tissue attachments, or blockages.
Study: NCT06248307

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Barrita experimental
Description: Nutritional advice, as well as administration of protein bars.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Barrita Placebo
Description: Nutritional advice, as well as administration of placebo bars.
Study: NCT05495386

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyposafe hypoglycaemia notification device (H02)
Description: The H02 device consists of two parts:~1. An implantable part which records the EEG signal and transmits the signal wirelessly to the external device.~2. The external device receiving signals and storing data from the implant.
Study: NCT06266130

Intervention type: DEVICE
Group type: OTHER
Intervention: Treatment Group Digital Bonding Tray
Description: The Digital Bonding Tray is used in orthodontic treatment of misaligned teeth and provides a method to accurately position orthodontic brackets onto a patient's teeth simultaneously during a single procedure.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control Group Direct Bonding
Description: The orthodontic brackets will be applied to Subject's teeth individually with direct bonding method.